Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation

NCT07349498 · tracked via the Priya Life Science China tracker

Sponsor

Peking University People's Hospital

Phase

Observational

Started

2026-01-01

Last updated

2026-01-16

Condition(s) studied

Hematopoietic Stem Cell TransplantationTransplant ComplicationCardiovascular Events

Study summary

This is a prospective, multicenter observational study for recipients of hematopoietic stem cell transplantation. Patients who underwent hematopoietic stem cell transplantation at the participating centers will be entrolled in the study. The clinical characteristics, laboratory profiles, management measures, and clinical outcomes such as post-transplant cardiovascular events will be prospectively collected.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients who undergo hematopoietic cell transplantation at any of the participating medical centers. Exclusion Criteria: * Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data. * Patient request to withdraw from the study.

Primary outcome measure(s)

Major adverse cardiovascular events (MACE) — At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.
Major adverse cardiovascular events (MACE) after hematopoietic stem cell transplantation.

Trial sites (16)

Facility	City	Region	Status
Chinese PLA General Hospital	Beijing	Beijing Municipality	Recruiting
Peking University First Hospital	Beijing	Beijing Municipality	Recruiting
Peking University People's Hospital	Beijing	Beijing Municipality	Recruiting
Peking University Third Hospital	Beijing	Beijing Municipality	Recruiting
Xinqiao hospital of the third military medical university	Chongqing	Chongqing Municipality	Recruiting
Sun Yat-sen University Cancer Center, Sun Yat-sen University	Guangzhou	Guangdong	Recruiting
Peking University Shenzhen Hospital	Shenzhen	Guangdong	Recruiting
First Affiliated Hospital of Harbin Medical University	Harbin	Heilongjiang	Recruiting
The First Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan	Recruiting
Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology	Wuhan	Hubei	Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei	Recruiting
First Affiliated Hospital Xi'an Jiaotong University	Xi'an	Shaanxi	Recruiting
Sichuan Provincial People's Hospital	Chengdu	Sichuan	Recruiting
Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences)	Tianjin	Tianjin Municipality	Recruiting
First Affiliated Hospital of Xinjiang Medical University	Ürümqi	Xinjiang	Recruiting
First Affiliated Hospital of Zhejiang University	Hangzhou	Zhejiang	Recruiting

More Peking University People's Hospital trials in China

Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors Recruiting

Research on the Application of Patient Navigation-based Management Model of Patients After LEEP Starting soon

IFN-α in Relapse Prevention. Starting soon

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer Recruiting

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment Recruiting

Other trials for the same condition

Population PK-guided ATG Dosing in Haplo-HSCT Recruiting

Posaconazole Tablet As Primary Prophylaxis of HSCT Patients with Gastrointestinal GVHD Enrolling by invitation

Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients Recruiting

Critical Illness After Hematopoietic Cell Transplantation Starting soon

Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07349498 on ClinicalTrials.gov ↗ ← All trials in China